Shuqiao Zhang1, Xinyu Li1, Yilu Zheng2

  • 1First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.

概括

氧化应激驱动肝细胞癌 (HCC) 的进展. 我们的研究确定了PRDX1作为预测HCC预后和免疫治疗反应的关键基因,提供了新的治疗点.